A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: a GINECO study

By Diéras Véronique   Guastalla Jean   Ferrero Jean   Curé Hervé   Weber Béatrice   Winckel Philippe   Lortholary Alain   Mayer Françoise   Paraiso Désiré   Magherini Emmanuelle   Pujade-Lauraine Eric  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 6, 2004-06 ,pp. : 489-495

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel (taxotere(R)) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer

By Le Chevalier T.   Monnier A.   Douillard J.Y.   Ruffie P.   Sun X.S.   Belli L.   Ibrahim N.   Bougon N.   Berille J.  

European Journal of Cancer, Vol. 34, Iss. 13, 1998-12 ,pp. : 2032-2036

Elsevier

Access to resources Recommend Favorite

Phase II Study of Gemcitabine and Docetaxel in Recurrent Platinum Resistant Ovarian Cancer

By Garcia Agustin A.   Yessaian Anne   Pham Huyen   Facio Grace   Muderspach Laila   Roman Lynda  

Cancer Investigation, Vol. 30, Iss. 4, 2012-04 ,pp. : 295-299

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

By De Lena M.   Lorusso V.   Latorre A.   Fanizza G.   Gargano G.   Caporusso L.   Guida M.   Catino A.   Crucitta E.   Sambiasi D.   Mazzei A.  

European Journal of Cancer, Vol. 37, Iss. 3, 2001-02 ,pp. : 364-368

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of docetaxel (Taxotere&unknown;) in heavily pretreated advanced breast cancer patients - a national cancer institute treatment referral center trial

By Bonneterre J.   Spielman M.   Guastalla J.-P.   Marty M.   Viens P.   Chollet P.   Roche H.   Fumoleau P.   Mauriac L.   Bourgeois H.   Namer M.   Bergerat J.P.   Misset J.-L.   Trandafir L.   Mahjoubi M.  

European Journal of Cancer, Vol. 35, Iss. 10, 1999-10 ,pp. : 1431-1439

Elsevier

Access to resources Recommend Favorite